GABRE
MOLECULAR TARGETgamma-aminobutyric acid type A receptor subunit epsilon
GABRE (gamma-aminobutyric acid type A receptor subunit epsilon) is targeted by 12 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting GABRE
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | gamma-Aminobutyric Acid | 3.22 | 24 |
| 2 | Pregnanolone | 2.08 | 7 |
| 3 | Apigenin 5,7,4'-trihydroxy-flavone, | 1.10 | 2 |
| 4 | chrysin | 1.10 | 2 |
| 5 | Androsterone | 1.10 | 2 |
| 6 | Bicuculline | 1.10 | 2 |
| 7 | Ciprofloxacin | 0.69 | 1 |
| 8 | Etiocholanolone | 0.69 | 1 |
| 9 | Etomidate Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or | 0.69 | 1 |
| 10 | Ondansetron | 0.69 | 1 |
| 11 | Picrotoxin | 0.69 | 1 |
| 12 | Triiodothyronine | 0.69 | 1 |
About GABRE as a Drug Target
GABRE (gamma-aminobutyric acid type A receptor subunit epsilon) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 12 compounds with documented GABRE interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
GABRE inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.